| Description | This product is a human neutralizing antibody clone 1382 specific for HCV E2, which is the mian target of Hepatitis C virus. It binds to the conserved epitope in the E2 front layer. It exhibits potent neutralizing ability against HCV and it inhibits infection of multiple HCV strains. This product has been tested by Enzyme-linked immunosorbent assay, Immunofluorescence and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | HCV |
| Epitope | It binds to the conserved epitope in the E2 front layer. |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; IF; Neut |
| Application Notes | This antibody has been detected by ELISA, Immunofluorescence (IF) and Neutralization assay. Neutralization assay (Neut): 50 μg/mL |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HCV E2 |
| Alternative Name | Hepatitis C virus envelope glycoprotein E2 |
| Research Area | Infectious Disease |
| Related Disease | Liver failure, Hepatocellular carcinoma |
